Related Experiment Video
Updated: Aug 10, 2026
10:10
Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
Published on: August 15, 2016
Cyclodextrins as new formulation entities and therapeutic agents
Sreevalli Sikharam1, Talmage D Egan, Steven E Kern
1Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84108, USA.
Current Opinion in Anaesthesiology
|March 15, 2006
Summary
Cyclodextrins are advancing drug formulations, particularly in anesthesia. New applications for anesthetic agents like propofol and rocuronium suggest a growing role for these compounds in medical practice.
Area of Science:
- Pharmaceutical Science
- Anesthesiology
- Drug Delivery Systems
Background:
- Cyclodextrins are established pharmaceutical excipients.
- Their use is expanding beyond traditional applications.
- Recent research highlights their potential in specialized medical fields.
Purpose of the Study:
- To review recent advancements in cyclodextrin applications for drug formulations.
- To emphasize the specific progress in the field of anesthesia.
Main Methods:
- Literature review of recent studies on cyclodextrin applications.
- Focus on formulations relevant to anesthesiology.
- Analysis of novel cyclodextrin-based drug delivery systems.
Main Results:
- Cyclodextrins are being developed for non-lipid formulations of anesthetic agents, such as propofol.
- Novel cyclodextrins are emerging as specific reversal agents for neuromuscular blockers like rocuronium.
- Cyclodextrin-containing polymers show promise in delivering nucleic acids and protein therapeutics.
Conclusions:
- Recent developments position cyclodextrins for potential integration into anesthesiology.
- Further research is needed to fully elucidate the clinical potential of cyclodextrins in anesthesia.
- Cyclodextrins represent a promising area for innovation in drug formulation and delivery.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...